HCA Healthcare raised its annual profit forecast on Tuesday, after beating Wall Street estimates for quarterly earnings, sending shares of the hospital operator up nearly 7% before the bell.
Here is how HCA Healthcare (HCA) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.
HCA Healthcare, Inc. will report earnings on Tuesday, July 23rd. I expect HCA to have a strong quarter based on reaffirmed guidance, industry trends, and consensus revisions upward. Multiple valuation methods signal HCA is fairly priced, while industry trends suggest balanced upside and downside. I continue to rate HCA a hold.
HCA Healthcare's (HCA) second-quarter earnings are likely to benefit from improved admissions and payer mix, partially offset by rising operating expenses.
HCA (HCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These healthcare businesses are booming. Vertex Pharmaceuticals is raking in approvals, cash, and profits.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
HCA (HCA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HCA Healthcare (HCA) remains well-poised for growth on the back of improved revenues, a well-diversified healthcare portfolio and solid cash-generating abilities.